LONDON – Medalliance SA says its sirolimus-coated balloon catheter for the treatment of coronary artery disease will be in U.S. patients this time next year, after the device was awarded a U.S. FDA breakthrough device designation. The device, called Selution, uses biodegradable polymer micro reservoirs to hold sirolimus, enabling the anti-restenotic drug to be released in a controlled and sustained way.